Form 4: NeoGenomics EVP Olivo Reports Equity Transactions
Insider Transaction Report
Alicia C. Olivo, EVP, GC & Business Development at NeoGenomics Inc., reported recent vesting of restricted stock units and associated tax-related dispositions, alongside an updated overview of her derivative holdings.
Summary
- Alicia C. Olivo, Executive Vice President, General Counsel & Business Development of NeoGenomics Inc. (NEO), reported changes in her beneficial ownership of company securities.
- On February 21, 2026, 21,079 shares of common stock were acquired upon the vesting of restricted stock units (RSUs), increasing her direct beneficial ownership to 96,399 shares.
- Concurrently, 8,295 shares of common stock were disposed of on February 21, 2026, to satisfy tax withholding obligations related to the RSU vesting, resulting in 88,104 shares beneficially owned.
- On February 23, 2026, an additional 8,443 shares of common stock were acquired from RSU vesting, bringing her direct beneficial ownership to 96,547 shares.
- Another 3,323 shares of common stock were disposed of on February 23, 2026, for tax withholding purposes, leaving her with 93,224 shares beneficially owned.
- The filing also details various derivative securities held, including Restricted Stock Units (RSUs), Performance Stock Units (PSUs), and Stock Options, with different grant dates, vesting schedules, and expiration dates.
- Notable derivative holdings include 42,159 RSUs (from a 02/21/2025 grant), 8,443 RSUs (from a 02/23/2024 grant), 6,503 RSUs (from a 05/11/2023 grant), and 59,382 RSUs that vested on 01/13/2026.
- Performance Stock Units include 19,508 (target, max 29,262) granted on 05/11/2023, and 25,330 (target, max 37,996) granted on 02/23/2024, with vesting tied to share growth and revenue growth goals.
- Stock options held range from exercise prices of $9.45 to $48.99, with expiration dates extending from September 30, 2026, to February 21, 2035, including a premium-price option granted on February 21, 2025, with an exercise price of $13.05.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a routine insider filing reflecting standard executive compensation practices, with no immediate positive or negative implications for the company's operational or financial performance.
Positives
- The vesting of restricted stock units indicates the executive's continued accumulation of equity in the company, aligning her interests with shareholders.
- The grants of performance stock units and stock options incentivize the executive to achieve specific share growth and revenue growth goals, potentially driving future company performance.
Negatives
- Disposition of shares for tax withholding purposes, while routine, reduces the executive's direct share count.
Future Outlook
The executive's future equity accumulation is tied to the vesting schedules of her outstanding Restricted Stock Units (RSUs) and Performance Stock Units (PSUs), which vest ratably over three to four years from their respective grant dates. Performance Stock Units are subject to the achievement of specific share growth and revenue growth goals. Stock options have various expiration dates, with the latest extending to February 21, 2035.
Industry Context
StockSavvy.ai notes that equity compensation, including RSUs, PSUs, and stock options, is a standard practice in the biotechnology and diagnostics industry to align executive incentives with shareholder value and long-term company performance. This filing reflects a routine aspect of executive compensation in the sector.
Comparison to Industry Standards
- StockSavvy.ai observes that the mix of time-based RSUs and performance-based PSUs, along with stock options, is consistent with executive compensation structures seen in comparable companies within the diagnostics sector, such as Guardant Health (GH) or Exact Sciences (EXAS).
- The use of premium-price stock options, as seen in the 02/21/2025 grant, is a less common but effective mechanism to further incentivize significant stock price appreciation, aligning with best practices for long-term value creation.
Stakeholder Impact
- Shareholders: The executive's equity holdings align her interests with shareholder value creation, particularly through performance-based awards.
- Employees: No direct impact on general employees is indicated by this filing, though executive compensation practices can influence overall company culture and compensation philosophy.
Next Steps
- Continued vesting of Restricted Stock Units and Performance Stock Units according to their respective schedules.
- Potential exercise of stock options prior to their expiration dates.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Grant date for 1,394 stock options with an exercise price of $19.12, expiring 09/30/2026. |
| 05/01/2020 | Grant date for 1,024 stock options with an exercise price of $27.34, expiring 05/01/2027. |
| 05/01/2021 | Grant date for 516 stock options with an exercise price of $48.99, expiring 05/01/2028. |
| 08/01/2021 | Grant date for 1,117 stock options with an exercise price of $46.1, expiring 08/01/2028. |
| 05/01/2022 | Grant date for 22,222 stock options with an exercise price of $9.45, expiring 05/01/2029. |
| 09/01/2022 | Grant date for 55,332 stock options with an exercise price of $10.05, expiring 09/01/2029. |
| 05/11/2023 | Grant date for 36,508 stock options with an exercise price of $19.65, expiring 05/11/2030. |
| 05/11/2023 | Grant date for 19,508 restricted stock units, vesting ratably over three years. |
| 05/11/2023 | Grant date for 19,508 performance stock units (target), with a maximum of 29,262 shares, vesting based on share growth goals. |
| 02/23/2024 | Grant date for 25,329 restricted stock units, vesting ratably over three years. |
| 02/23/2024 | Grant date for 42,344 stock options with an exercise price of $16.45, expiring 02/23/2034. |
| 02/23/2024 | Grant date for 25,330 performance stock units (target), with a maximum of 37,996 shares, vesting based on share growth and revenue growth goals. |
| 02/21/2025 | Grant date for 63,238 restricted stock units, vesting ratably over three years. |
| 02/21/2025 | Grant date for 107,450 premium-price stock options with an exercise price of $13.05, expiring 02/21/2035. |
| 01/13/2026 | Vesting date for 59,382 Restricted Stock Units. |
| 02/21/2026 | Transaction date: Acquisition of 21,079 common stock shares from RSU vesting and disposition of 8,295 shares for tax withholding. |
| 02/23/2026 | Transaction date: Acquisition of 8,443 common stock shares from RSU vesting and disposition of 3,323 shares for tax withholding. |
| 02/24/2026 | Signature date of the Form 4 filing. |
| 05/11/2026 | Expiration date for 19,508 Performance Stock Units granted on 05/11/2023. |
| 09/30/2026 | Expiration date for 1,046 Stock Options granted on 09/30/2019. |
| 02/23/2027 | Expiration date for 25,330 Performance Stock Units granted on 02/23/2024. |
| 05/01/2027 | Expiration date for 1,024 Stock Options granted on 05/01/2020. |
| 05/01/2028 | Expiration date for 516 Stock Options granted on 05/01/2021. |
| 08/01/2028 | Expiration date for 1,117 Stock Options granted on 08/01/2021. |
| 05/01/2029 | Expiration date for 22,222 Stock Options granted on 05/01/2022. |
| 09/01/2029 | Expiration date for 46,355 Stock Options granted on 09/01/2022. |
| 05/11/2030 | Expiration date for 36,508 Stock Options granted on 05/11/2023. |
| 02/23/2034 | Expiration date for 42,344 Stock Options granted on 02/23/2024. |
| 02/21/2035 | Expiration date for 107,450 Stock Options granted on 02/21/2025. |
Recommendation
holdThis Form 4 filing details routine equity compensation transactions for an executive, including RSU vesting and tax-related share dispositions. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are standard for executive compensation and do not signal any significant positive or negative developments for NeoGenomics.
Keywords
NeoGenomics, NEO, Alicia Olivo, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Performance Stock Units, Equity Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.